Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01340963
Other study ID # 012345/96
Secondary ID
Status Completed
Phase N/A
First received April 21, 2011
Last updated December 9, 2013
Start date June 1995
Est. completion date December 2012

Study information

Verified date December 2013
Source Universidade Gama Filho
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Observational

Clinical Trial Summary

The study investigated 100 subjects, both genders, with chronic Chagas disease, confirmed by at least two distinct serological tests, and classified according to Los Andes classification in a long term follow-up aiming at identifying the predictive value of the signal-averaged electrocardiogram for cardiac death and ventricular tachycardia.

All subjects admitted to the study were submitted to clinical history taking, physical examination, and noninvasive assessment, including blood pressure measurement, resting 12-lead surface electrocardiogram, 24h ambulatory electrocardiogram monitoring, M-Mode/two-dimensional echocardiogram, signal-averaged electrocardiogram in both time and frequency domains. Selected subjects were further submitted to treadmill stress test and coronary angiography to rule out coronary heart disease.

Subjects were followed by non-investigational primary care assistance at three to six months scheduled clinical visits on an outpatients basis. Both noninvasive and invasive evaluation during follow-up were requested at discretion of primary evaluation. Adverse outcomes were ascertained by review of medical records and active contact to either study subjects or their relatives.


Description:

Admission:

Longitudinal prospective study, with a cohort of 100 consecutive outpatient subjects (34 to 74 years old; 31 females) with Chagas' disease followed-up for at least 10 years at the cardiomyopathy outpatient clinic of University Hospital, Rio de Janeiro, RJ, Brazil, a tertiary care center. Enrollment was from 1995 to 1999. Subjects were born in endemic regions of Minas Gerais, Goias or Bahia States of Brazil and Chagas' disease was diagnosed on basis of two positive serum tests, hemagglutination cruzipain-ELISA and indirect immunofluorescence. All subjects were referred to the arrhythmia for risk stratification. At the time of admission none had received nitroderivative therapy. Subjects were classified according to the severity of heart involvement according to Los Andes classification, and divided into three groups: class I - 28 subjects (group 1), class II - 48 subjects (group 2), and class III - 24 subjects (group 3). Clinical and laboratory data were assessed during a personal interview and review of medical records. On admission, all subjects were in New York Heart Association functional class I or II, had normal sinus rhythm and normal PR intervals. Exclusion criteria at initial enrollment were: any degree of atrioventricular block or non-sinus rhythm, previous documented acute coronary events (unstable angina or myocardial infarction), chronic obstructive pulmonary disease, rheumatic valvular heart disease, alcohol addiction, thyroid dysfunction or abnormal serum electrolytes. Treadmill stress test and/or coronary artery angiogram were indicated in selected subjects to rule out concomitant coronary artery disease. World Health Organization and Helsinki Treaty regulations reviewed in Venice (1983) were followed and all subjects provided informed consent to participate.

Clinical follow-up:

All subjects have been followed-up by the same team of physicians. Medical visits have been scheduled at the outpatient clinics in a three to six-month interval. Medications were prescribed at the discretion of the physician who performed the primary evaluation. Body weight varied <2 kg during follow-up, and serum potassium varied from 3.5 to 5 milliequivalent/L. Mild systemic arterial hypertension (systolic arterial pressure ranging from 140 mmHg and 155 mmHg, or diastolic arterial pressure ranging from 90 mmHg and 105 mmHg) was observed in 41% of the subjects and all received anti-hypertensive medication (converting enzyme inhibitors, diuretics, vasodilators and/or beta-blockers) at the discretion of the physician who performed the primary evaluation in order to reduce blood pressure levels to less than 140/90 mmHg. All regularly followed at scheduled clinical visits. The endpoints were described elsewhere in this registry. All causes of adverse events were ascertained by active search of relatives and review of the medical records.

Resting surface 12-lead ECG and plain chest roentgenogram

For each patient, standard resting 12-lead ECGs were recorded in the supine position (with simultaneous 3-lead acquisition) with a Cardimax ECAPS 12 2000 Compliant Electrocardiograph (Nihon-Kohden Co, Tokyo, Japan). Electrocardiographic abnormalities were classified according to standard criteria for conduction disturbances (intraventricular and atrioventricular), chamber overload, and abnormal Q waves [11]. The electrocardiographic variables assessed is sinus rhythm were: maximum P-wave duration and PR interval (typically in lead II), QRS complex duration (the longest ventricular duration in precordial leads), maximal absolute QRS complex in any precordial lead, presence of bundle branch block and/or left fascicular-block, presence of abnormal Q waves (Q-wave, defined as the first QRS deflection >1-mm deep and >0.04-ms wide), and left atrial overload (P-wave duration in lead II >110 ms or Morris index in V1 >4 millivolt.ms). In antero-septal leads (V1, V2 and V3) and in inferior leads (L2, L3 and aVF) the presence of Q-wave in two out of three leads was considered abnormal. An independent observer blind to the study analyzed the electrocardiographic records that were automatically obtained from electrocardiograph equipment. Subsequent 12-lead resting ECGs were recorded at each clinical visit in order to assess cardiac rhythm during follow-up. Plain chest roentgenogram was carried out on the same day and cardiomegaly was defined by a cardiothoracic ratio of more than 0.50.

M-mode/2-D Echocardiogram

M-mode and two-dimensional echocardiograms were performed using an Apogee CX-200 equipment (ATL, Bothell, Washington, USA) with a 4-megahertz broadband transducer. The echocardiograms were analyzed by a trained observer blinded to the study protocol Echocardiographic parameters were assessed according to standard procedures of the Section of Echocardiography of the Department of Cardiology, with special care taken to detect left ventricular apical aneurysms. The echocardiographic parameters assessed were left ventricular ejection fraction (LVEF) calculated by the teichholz method, left atrial diameter (LAD), presence of pulmonary arterial hypertension (defined as maximal pulmonary arterial pressure > 30 mmHg, diastolic dysfunction, and the presence of an apical aneurysm. Normal cut-off value for LVEF was defined as >50%. Routine echocardiograms were performed in order to track changes in LVEF during follow-up.

24h Ambulatory ECG Monitoring

Twenty-four-hour ambulatory ECG monitoring was performed using a three-channel DMS-cassette-tape recorder and carefully analyzed using the Del-Mar Avionics StrataScan System (Del Mar Avionics, Irvine, California, USA) by a trained observer blind to the study in order to assess the presence of ventricular arrhythmia and atrioventricular conduction disturbances. Variables assessed in the 24h ambulatory ECG were: i) isolated premature supraventricular contractions ii) nonsustained supraventricular tachycardia defined as a sequence of three of more supraventricular ectopic beats, iii) isolated premature ventricular contractions, and iv) ventricular tachycardia episodes (defined as: heart rate >100 bpm, QRS duration >120 ms, three or more consecutive ventricular complexes, and atrial-ventricular dissociation).

The standard-deviation of all consecutive normal interbeat intervals in 24h (24h SDNN) was employed to assess heart rate variability. Normal cut-off point was defined at >=100ms. During follow-up, 24h ambulatory ECG were performed at the discretion of attending physician's judgment in order to assess cardiac rhythm and arrhythmia. One trained specialist blind to Los Andes classification groups analyzed all tape recordings immediately after their acquisition.

Signal-averaged electrocardiogram

Signal-averaged electrocardiogram (SAECG) was employed to asses the presence of both ventricular late potentials and intraventricular electrical transients (IVET).

SAECG was acquired in sinus rhythm with a Predictor-IIc equipment (ART Inc., Fitchburg, Massachusetts, USA) using modified XYZ Frank orthogonal leads and QRS-triggered coherent-averaged up to the noise level of 0.3 microvolt. SAECGs were analyzed in both time and frequency domains by an independent observer blinded to the study patients information. After signal average ECG acquisition, time domain analysis was carried out on vector magnitude (VM), using a bidirectional 4th order 40 Hz to 250 Hz band-pass Butterworth filter. The variables extracted from VM were: duration of VM (DUR [ms]), root-mean-squared voltage of last 40ms of VM (RMS40[microvolt]) duration of potentials below 40 microvolt at the terminal portion of VM (LAS40[ms]). Due to the presence of bundle branch block as a common finding in Chagas disease, normal cut-off point for DUR was defined at >150ms.

The onset and offset points of VM delimited the analytic region for frequency domain analysis, by using the spectral turbulence analysis approach. The analytic region in VM was preprocessed to extract the first derivative, aiming at removing the high-amplitude low-frequency components. The derived signal was cut into slices to build a power spectral density time-frequency map by applying the short-time Fourier transform. Each data segment was limited in 25 ms, with 2 ms interval between successive segments to assure adequate time-resolution, tapered by a Blackmann-Harris window after mean removal, and zero-padded to 64 points. After Fourier transform of a particular segment, its spectral amplitude was squared to obtain the estimated power spectral density function. Successive power spectral density function estimates in the analytic region were attached in a three-dimensional map. The boundaries of the analytic region (up to 200 ms duration) were placed 25 ms prior to the onset of the VM and to a point on the ST segment 50 ms after the offset of the VM. In the time frequency map, spectral turbulence was studied by comparing sequential spectral estimates. We calculated Pearson's correlation coefficient between adjacent power spectral function estimates throughout ventricular activation, and deployed the correlation coefficients in a time series, of which the mean and the standard deviation of the intersegment spectral correlation (abbreviated as MSC and SSC, respectively) were calculated. Additionally, we calculated the frequency corresponding to 80% of the total area under a particular power spectral function estimate, starting at zero Hz, which practically represented the edge or the border, and deployed the edge frequency, thus calculated, in a time series. The mean and the standard deviation of the electrical transients (abbreviated as MET and SET, respectively) of the edge frequency series were extracted. Power spectral estimates were limited to the range from 0 to 300 Hz in order to avoid interference of high frequency noise during correlation. MSC and SSC were multiplied by 100 to simplify calculations. Normality threshold values have been defined previously as MSC>94, SSC<=6, MET<=78 and The SET<=31. The presence of intraventricular electrical transients (IVET+) was optimally defined when 2 out of 4 variables were outside normality range. We used the above method based on our hypothesis that the presence of high frequency electrical transients, representing underlying electrically unstable myocardial areas, would determine the reduction of intersegment correlation. Likewise, high frequency transients would increase the energy content of a spectral estimate and the shift the spectral border rightward, to a higher frequency.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2012
Est. primary completion date March 2001
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Clinically stable outpatients with at least 10 years of regular outpatients follow-up and positive epidemiological history and serological confirmation of Chagas disease with ate least two immunological tests

Exclusion Criteria:

- Any degree of atrioventricular block or non-sinus rhythm

- Previous documented acute coronary events (due to documented obstructive epicardial coronary vessels)

- Chronic obstructive pulmonary disease

- Rheumatic valvular heart disease

- Alcohol addiction

- Thyroid dysfunction

- Abnormal serum electrolytes and biochemical abnormalities

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Brazil Hospital Universitário Pedro Ernesto Rio de Janeiro RJ
Brazil Instituto Nacional de Cardiologia Rio de Janeiro RJ
Brazil Universidade Gama Filho Rio de Janeiro RJ
United States University of Texas at Houston Houston Texas

Sponsors (4)

Lead Sponsor Collaborator
Universidade Gama Filho Instituto Nacional de Cardiologia de Laranjeiras, Rio de Janeiro State University, The University of Texas Health Science Center, Houston

Countries where clinical trial is conducted

United States,  Brazil, 

References & Publications (18)

Benchimol Barbosa PR. Noninvasive prognostic markers for cardiac death and ventricular arrhythmia in long-term follow-up of subjects with chronic Chagas' disease. Braz J Med Biol Res. 2007 Feb;40(2):167-78. — View Citation

Benchimol-Barbosa PR, Barbosa-Filho J. Atrial mechanical remodeling and new onset atrial fibrillation in chronic Chagas' heart disease. Int J Cardiol. 2008 Jul 21;127(3):e113-5. Epub 2007 Aug 8. — View Citation

Benchimol-Barbosa PR, Barbosa-Filho J. Mechanical cardiac remodeling and new-onset atrial fibrillation in long-term follow-up of subjects with chronic Chagas' disease. Braz J Med Biol Res. 2009 Mar;42(3):251-62. — View Citation

Benchimol-Barbosa PR, Duque GS, Barbosa EC, Bomfim AS, Dantas-Carletti MS, Barbosa-Filho J. High spectral turbulence in signal-averaged electrocardiogram is an independent predictor for cardiac death in long-term follow-up of subjects with chronic Chagas

Benchimol-Barbosa PR, Duque GS, Barbosa-Filho J. Long term cardiac remodelling in chronic Chagas' heart disease. Eur Heart J; 2008. 29(suppl 1): 441-441. doi:10.1093/eurheartj/ehn375

Benchimol-Barbosa PR, Kantharia BK, Carvalhaes CG. Nonlinear Dynamics in Long-Term Left Ventricular Remodeling in Chagas Heart Disease and Adverse Outcomes: SEARCH-Rio Substudy. Circulation Research. 2012;111:A351

Benchimol-Barbosa PR, Muniz RT. Ventricular late potential duration correlates to the time of onset of electrical transients during ventricular activation in subjects post-acute myocardial infarction. Int J Cardiol. 2008 Sep 26;129(2):285-7. Epub 2007 Aug 10. — View Citation

Benchimol-Barbosa PR, Nasario-Junior O, Nadal J. The effect of configuration parameters of time-frequency maps in the detection of intra-QRS electrical transients of the signal-averaged electrocardiogram: impact in clinical diagnostic performance. Int J Cardiol. 2010 Nov 5;145(1):59-61. doi: 10.1016/j.ijcard.2009.04.013. Epub 2009 May 9. — View Citation

Benchimol-Barbosa PR, Tura BR, Barbosa E, Barbosa-Filho J, Kantharia BK. A Novel Risk Score Based on Noninvasive ECG Monitoring Aiming at Predicting Ventricular Tachycardia and Cardiac Death in Chronic Chagas Disease. Circulation. 2010; 122: A19759.

Benchimol-Barbosa PR, Tura BR, Barbosa EC, Barbosa-Filho J, Kantharia BK. A novel risk score for predicting cardiac death in chronic chagas heart disease based on spectral turbulence analysis of the signal-averaged ECG. Eur Heart J; 2010. 31(suppl 1): 163

Benchimol-Barbosa PR, Tura BR, Barbosa EC, Kantharia BK. Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease - the SEARCH-RIO study. Braz J Med Biol Res. 2013 Oct 22;46(11):974-984. [Epub ahe — View Citation

Benchimol-Barbosa PR, Tura BR, Barbosa-Filho J, Kantharia BK. Increasing 24h incidence of isolated PVC is associated with growing complexity and incidence of cardiac tachyarrhythmia in Chagas heart disease. Eur Heart J; 2010. 31(suppl 1): 480-480. doi:10.

Benchimol-Barbosa PR. Cardiac remodeling and predictors for cardiac death in long-term follow-up of subjects with chronic Chagas' heart disease: a mathematical model for progression of myocardial damage. Int J Cardiol. 2009 Jan 24;131(3):435-8. Epub 2007 — View Citation

Benchimol-Barbosa PR. Clinical characteristics of spontaneous ventricular tachycardia episodes associated with unfavorable prognosis in chronic Chagas disease. Eur Heart J; 2010. 31(suppl 1): 480-480. doi:10.1093/eurheartj/ehq288

Benchimol-Barbosa PR. Nonlinear mathematical model for predicting long term cardiac remodeling in Chagas' heart disease: introducing the concepts of 'limiting cardiac function' and 'cardiac function deterioration period'. Int J Cardiol. 2010 Nov 19;145(2) — View Citation

Benchimol-Barbosa PR. Predictors of mortality in Chagas' disease: the impact of atrial fibrillation and oral transmission on infected population. Int J Cardiol. 2009 Apr 3;133(2):275-7. doi: 10.1016/j.ijcard.2007.11.053. Epub 2008 Jan 15. — View Citation

Benchimol-Barbosa PR. Trends on acute Chagas' disease transmitted by oral route in Brazil: steady increase in new cases and a concealed residual fluctuation. Int J Cardiol. 2010 Dec 3;145(3):494-6. doi: 10.1016/j.ijcard.2009.08.030. Epub 2009 Sep 16. — View Citation

PR Benchimol-Barbosa. Ventricular tachyarrhythmic events triggers in chronic Chagas disease. Eur Heart J; 2010. 31(suppl 1): 481-481. doi:10.1093/eurheartj/ehq288

* Note: There are 18 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac death [Time Frame: up to 10 years ] Defined as intractable heart failure, arrhythmic, coronary occlusion, or sudden death.
Assessment twice an year by active and direct contact to subjects or relatives and review of medical records.
up tp 10 years No
Secondary Ventricular tachycardia New onset ventricular tachycardia defined as symptomatic (palpitations, dizziness or syncope), >=3 consecutive beats, bundle branch block configuration, ventricular rate >100bpm, atrial-ventricular dissociation.
Assessed with 24h-ambulatory electrocardiogram monitoring requested at discretion of non-investigational primary evaluation and confirmed by review of medical records.
up to ten years No
Secondary Stroke, either fatal or nonfatal Evidence of clinically definite stroke (focal neurological deficits persisting for more than 24 hours) confirmed or not by non-investigational CT.
Assessment twice an year by active and direct contact to patents or relatives and review of medical records.
up to 10 years No
Secondary Persistent atrial fibrillation Irregular non-sinus interbeat interval, lasting more that 24h, confirmed by either non-investigational 24h ambulatory electrocardiogram monitoring or resting 12-lead surface electrocardiogram two to four times a year.
Assessment by review of medical records.
up to 10 years No
Secondary Cardiac function and dimensions Non-investigational M-mode/2-D echocardiographic evaluation at the discretion of primary care assistance.
Assessment by review of medical records.
up to 10 years No
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis